37 Results

People

  1. Aghajanian
    Aghajanian
  2. Gerecitano
    Gerecitano
  3. Moskowitz
    Moskowitz
  4. O'connor
    O'connor
  5. Zelenetz
    Zelenetz
  6. Gonen
    Gonen
  7. Spriggs
    Spriggs
  8. Dumitrescu
    Dumitrescu
  9. Feldstein
    Feldstein
  10. Hamlin
    Hamlin

Groups

  1. Department of Medicine (23)
  2. Hematologic Malignancies, Division of (15)
  3. Solid Tumor Oncology Division (11)
  4. Center for Hematologic Malignancies (9)
  5. Biostatistics Service (8)
  6. Epidemiology and Biostatistics (8)
  7. Center for Pancreatic Cancer Research (6)
  8. Nursing (6)
  9. GDMT, Medicine (5)
  10. Gynecologic Medicine Service (5)
  1. "boronic acids"
Formats
  1. Journal Article (37)
Groups
  1. Department of Medicine (23)
  2. Hematologic Malignancies, Division of (15)
  3. Solid Tumor Oncology Division (11)
  4. Center for Hematologic Malignancies (9)
  5. Biostatistics Service (8)
  6. Epidemiology and Biostatistics (8)

More Groups

People
  1. Owen O'connor (9)
  2. Andrew Zelenetz (5)
  3. Carol Aghajanian (5)
  4. Craig Moskowitz (5)
  5. John Gerecitano (5)
  6. David Spriggs (4)

More People

Years
  1. 2014 (1)
  2. 2012 (4)
  3. 2011 (2)
  4. 2010 (2)
  5. 2009 (6)
  6. 2008 (2)

More Years

Publications
  1. British Journal of Haematology (5)
  2. Blood (4)
  3. Clinical Cancer Research (4)
  4. Journal of Clinical Oncology (4)
  5. Current Treatment Options in Oncology (2)
  6. Journal of the National Comprehensive Cancer Network (2)

More Publications

Publishers
  1. John Wiley & Sons (5)
  2. Springer (5)
  3. American Association for Cancer Research (4)
  4. American Society of Clinical Oncology (4)
  5. American Society of Hematology (4)
  6. Elsevier Inc. (2)

More Publishers

Results (37)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial
    Journal Article

    O'Connor, O. A.; Moskowitz, C.; Portlock, C.; Hamlin, P.; Straus, D.; Dumitrescu, O.; Sarasohn, D.; Gonen, M.; Butos, J.; Neylon, E.; more...
    British Journal of Haematology (2009)

    Fulltext@MSK | Save
  • Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
    Journal Article

    Kumar, S.; Giralt, S.; Stadtmauer, E. A.; Harousseau, J. L.; Palumbo, A.; Bensinger, W.; Comenzo, R. L.; Lentzsch, S.; Munshi, N.; Niesvizky, R.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
    Journal Article

    Gerecitano, J.; Portlock, C.; Moskowitz, C.; Hamlin, P.; Straus, D.; Zelenetz, A. D.; Zhang, Z.; Dumitrescu, O.; Sarasohn, D.; Lin, D.; more...
    British Journal of Haematology (2009)

    Fulltext@MSK | Save
  • The future of small molecule inhibitors in lymphoma
    Journal Article

    Gerecitano, J.
    Current Oncology Reports (2009)

    Fulltext@MSK | Save
  • A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
    Journal Article

    Aghajanian, C.; Blessing, J. A.; Darcy, K. M.; Reid, G.; DeGeest, K.; Rubin, S. C.; Mannel, R. S.; Rotmensch, J.; Schilder, R. J.; Riordan, W.
    Gynecologic Oncology (2009)

    Fulltext@MSK | Save
  • Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
    Journal Article

    Rosenberg, J. E.; Halabi, S.; Sanford, B. L.; Himelstein, A. L.; Atkins, J. N.; Hohl, R. J.; Millard, F.; Bajorin, D. F.; Small, E. J.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
    Journal Article

    Paoluzzi, L.; Gonen, M.; Bhagat, G.; Furman, R. R.; Gardner, J. R.; Scotto, L.; Gueorguiev, V. D.; Heaney, M. L.; Manova, K.; O'Connor, O. A.
    Blood (2008)

    Fulltext@MSK | Save
  • Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis
    Journal Article

    Wu, K. D.; Zhou, L.; Burtrum, D.; Ludwig, D. L.; Moore, M. A. S.
    Cancer Immunology, Immunotherapy (2007)

    Fulltext@MSK | Save
  • A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Kelly, W. K.; Slovin, S.; Ryan, C.; Eicher, C.; Heller, G.; Scher, H. I.
    Journal of Urology (2007)

    Fulltext@MSK | Save
  • Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: Therapeutic implications
    Journal Article

    Kukreja, A.; Hutchinson, A.; Mazumder, A.; Vesole, D.; Angitapalli, R.; Jagannath, S.; O'Connor, O. A.; Dhodapkar, M. V.
    British Journal of Haematology (2007)

    Fulltext@MSK | Save